Blessing for the bleeder: Bevacizumab in hereditary hemorrhagic telangiectasia

Clinical Medicine and Research

Volumn 13, Issue 1, 2015, Pages 32-35

  Epperla, Narendranath ^a,b   Hocking, William ^a  

^a MARSHFIELD CLINIC   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bevacizumab; Dosing; Epistaxis; Hereditary hemorrhagic telangiectasia (HHT)

Indexed keywords

BEVACIZUMAB; FERRITIN; HEMOGLOBIN; IRON; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; EPISTAXIS; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HUMAN; IRON DEFICIENCY ANEMIA; LAPAROSCOPIC SURGERY; MELENA; MENORRHAGIA; MIDDLE AGED; PULMONARY ARTERIOVENOUS FISTULA; RENDU OSLER WEBER DISEASE; SALPINGOOOPHORECTOMY; VAGINAL HYSTERECTOMY; BLOOD; CHRONIC DISEASE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

BEVACIZUMAB; CHRONIC DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MIDDLE AGED; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84928956216     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2013.1205     Document Type: Article

References (16)

1. Fleagle JM, Bobba RK, Kardinal CG, Freter CE. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Am J Med Sci 2012;343:249–251.
2. Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factorbeta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818–928.
3. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360:2143–2144.
4. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;361:931; author reply 931–932.
5. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948–955.
6. Retornaz F, Rinaldi Y, Duvoux C. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;61: 931; author reply 931–932.
7. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantion in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210–213.
8. Flieger D, Hainke S. Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631–632.
9. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011;364:688–689.
10. Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011;90:611–612.
11. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66–67.
12. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345–351.
13. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189–195.
14. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007;109:19531961.
15. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102:898–901.
16. Ge ZZ, Chen HM, Gao YJ, Liu WZ, Xu CH, Tan HH, Chen HY, Wei W, Fang JY, Xiao SD. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011;141:1629–1637.